Skip to main content
. 2017 Dec 14;2017:8927473. doi: 10.1155/2017/8927473

(b).

Outcome studies
Study name Group randomization Patients (n) Age (years) Smoking (%) Statin use (%) Aspirin use (%) Mean follow-up(years) Silent CHD-ischaemia (%) Main Outcome
COURAGE (Boden et al. [135]) Medical therapy plus PCI with bare-metal stenting 1149 61.5 ± 10.1 23 86 96 4.6 NA (all participants had known CHD) No difference for the primary endpoint of death from any cause and nonfatal MI (cumulative incidence approximately 19% in both groups; HR: 1.05; 95% CI: 0.87–1.27; P = 0.62). No significant difference in rates of hospitalization for acute coronary syndrome (approximately 12% in both groups; HR: 1.07; 95% CI: 0.84–1.37; P = 0.56). Patients in PCI group underwent significantly fewer subsequent revascularization procedures (21% versus 33%, HR: 0.60, 95% CI: 0.51–0.71)
Medical therapy alone 1138 61.8 ± 9.7 23 89 95
BARI 2D (Mori Brooks et al. [136]) Revascularization (PCI or CABG) with intensive medical therapy (IMT) 953 62.3 ± 8.8 10.4 94.6 93.5 5 NA (all participants had known CHD) No difference in primary endpoints of survival or freedom from major CVD events (death, MI, or stroke) between the revascularization and IMT groups (88.3% versus 87.8% and 77.2% versus 75.9%, resp.)
IMT alone 991 62.4 ± 9.0 11.2 95.4 94.2
BARDOT (Zellweger et al. [121]) Positive MPI with SPECT (MPS) 87 65 ± 7 32 66 63 2 22 Patients with abnormal MPS randomized to medical versus invasive-medical strategies had similar hard event rates ((HR: 0.36; 95% CI: 0.07 to 1.81; P = 0.215), but more ischemic or new scar findings on repeat scintigraphy (54.3% versus 15.8%; P < 0.001)
Negative MPS 313 63 ± 8 18 55 50

CHD: coronary heart disease; ECG: electrocardiogram; echo: echocardiography; NA: not applicable; DIAD: Detection of Ischemia in Asymptomatic Diabetics; DYNAMIT: Do You Need to Assess Myocardial Ischemia in Type-2 diabetes; DADDY-D: Does coronary Atherosclerosis Deserve to be Diagnosed earlY in Diabetic patients; COURAGE: Clinical Outcomes Using Revascularization and Aggressive Drug Evaluation; BARI 2D: Bypass Angioplasty Revascularization Investigation 2 Diabetes; BARDOT: Basel Asymptomatic high-Risk Diabetics' Outcome Trial.